Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant-Reference-Cited by-同舟云学术

Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant

Published:2021-11-30 Issue:2 Volume:57 Page:312-314
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Giaccone Luisa^ORCID,Brunello Lucia,Londono Jaime Suarez,Scaldaferri Matilde,Cerrano Marco^ORCID,Redoglia Valter,Omedè Paola,Lia Giuseppe,Massaia Massimo,Ferrero Dario,Cavallo Federica^ORCID,Bringhen Sara,Leone Sarah,Cattel Francesco,Francisci Tiziana,Tassi Valter,Evangelista Andrea,Boccadoro Mario^ORCID,Bruno Benedetto

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01541-1.pdf

Reference12 articles.

1. Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17:e31–8.

2. Daller J. Biosimilars: A consideration of the regulations in the United States and European union. Regul Toxicol Pharm. 2016;76:199–208.

3. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205.

4. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program. 2003:419–37.

5. Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504–11.